Healthcare / Medical DevicesShanghai
$55.34
-0.66 (-1.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $169.9M · quality 74.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.5B
P/E
20.1x
↓EV/EBITDA
12.1x
↓ROE
8.8%
↑Gross Margin
71.1%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.0%
FCF CAGR
-3.0%
FCF margin
14.8%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $593.7M · net income $221.7M · FCF $87.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $593.7M | $593.7M | $636.6M | $508.7M | $371.1M |
| Net Income | $221.7M | $221.7M | $293.4M | $217.2M | $145.0M |
| EBITDA | $275.7M | $275.7M | $352.8M | $258.3M | $171.9M |
| EPS | 2.75 | 2.75 | 3.64 | 2.99 | 2.39 |
| Gross Margin | 71.1% | 71.1% | 72.1% | 70.9% | 68.1% |
| Operating Margin | 37.7% | 37.7% | 45.3% | 44.7% | 43.0% |
| Net Margin | 37.3% | 37.3% | 46.1% | 42.7% | 39.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 17.48 | 17.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $87.7M | $87.7M | $266.2M | $169.9M | $96.3M |
| Returns | |||||
| ROE | 8.8% | 8.8% | 12.2% | 9.8% | 38.0% |
| Valuation | |||||
| P/E | 20.05 | 20.05 | 15.55 | 28.43 | — |
| EV/EBITDA | 12.05 | 12.05 | 10.02 | 16.34 | — |
| P/B | 1.77 | 1.77 | 1.90 | 2.80 | — |
| Growth & Yield | |||||
| Revenue Growth | -6.7% | -6.7% | 25.1% | 37.1% | — |
| EPS Growth | -24.5% | -24.5% | 21.7% | 25.3% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
21.3%
EPS terminal req.
$4.91
Spread vs growth
-45.8%
5Y implied EPS CAGR
16.7%
EPS terminal req.
$5.94
Spread vs growth
-41.1%
10Y implied EPS CAGR
13.3%
EPS terminal req.
$9.57
Spread vs growth
-37.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.5%
Start / end P/E
17.3x → 20.1x
EPS bridge
3.64 → 2.75
Residual
-4.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.